2-(3-chloropropyl)-2H-naphth<1,8-cd>isothiazole 1,1-dioxide | 127625-83-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 2-(3-chloropropyl)-2H-naphth<1,8-cd>isothiazole 1,1-dioxide
• 英文别名: 2(3-Chloropropyl)naphtho[1,8-cd]isothiazole 1,1-dioxide；3-(3-chloropropyl)-2λ6-thia-3-azatricyclo[6.3.1.04,12]dodeca-1(11),4,6,8(12),9-pentaene 2,2-dioxide
• CAS: 127625-83-6
• 化学式: C₁₃H₁₂ClNO₂S
• 分子量: 281.763
• InChiKey: AKJRPLOEVCFABS-UHFFFAOYSA-N

物化性质

• 熔点：
  78 °C
• 沸点：
  489.5±47.0 °C(Predicted)
• 密度：
  1.423±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  45.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(3-chloropropyl)-2H-naphth<1,8-cd>isothiazole 1,1-dioxide 在 sodium hydride 、 碳酸氢钠 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 22.0h， 生成 2-<3-(4-(1-methyl-1H-indol-3-yl)-1,2,3,6-tetrahydro-1-pyridinyl)propyl>-2H-naphth<1,8-cd>isothiazole 1,1-dioxide
  参考文献：
  名称：

  新的吲哚衍生物作为有效的和选择性的5-羟色胺摄取抑制剂。

  摘要：

  为了寻找新的5-HT摄取抑制剂，已经制备了一系列新的吲哚衍生物（2-28）。在DMF或THF的回流下，在碱的存在下，通过将N-（氯烷基）萘磺酰胺衍生物与适当的胺缩合获得这些化合物。除了哌嗪衍生物20（85％）以外，产率中等（12-56％）。测量了化合物对摄取位点和5-HT 2，α1和D 2受体的亲和力。通过5-HTP诱导症状的增强作用在体内研究了某些化合物。最有效和选择性最大的化合物（摄取的5-HT2与α1，D2位点相比）含有3-[（（4-哌啶基）甲基]吲哚部分。5-氟-3-[（4-哌啶基）甲基]吲哚本身（化合物1）对摄取位点显示出高亲和力，但缺乏体内活性。该化合物的N-甲基化消除了亲和力。相比之下，通过连接至萘磺胺或相关杂环的双碳链进行的N取代导致化合物对摄取位点表现出高亲和力。其中之一是1- [2- [4-（（5-氟-1H-吲哚-3-基）甲基-1-哌啶基]乙基] -5,6-二氢-1H，4H-1

  DOI：

  10.1021/jm00061a010
• 作为产物：
  描述：

  1,8-萘磺内酰胺 、 1-溴-3-氯丙烷 在 sodium hydride 作用下， 生成 2-(3-chloropropyl)-2H-naphth<1,8-cd>isothiazole 1,1-dioxide
  参考文献：
  名称：

  Naphthosultam derivatives: a new class of potent and selective 5-HT2 antagonists

  摘要：

  A series of 2-(aminoalkyl)naphth[1,8-cd]isothiazole 1,1-dioxides was synthesized and examined in various receptor binding tests. Most compounds demonstrated high affinity for the 5-HT2 receptor with moderate to high selectivity. A member of this series, compound 24 (RP 62203), displays high 5-HT2 receptor affinity (K(i) = 0.26 nM), which is respectively more than 100 and 1000 times higher than its affinity for alpha-1 (K(i) = 38 nM) and D2 (K(i) > 1000 nM) receptors. This compound is a potent orally effective and long lasting 5-HT2 antagonist in the mescaline-induced head-twitches test in mice and rats.

  DOI：

  10.1021/jm00112a025

文献信息

• Heterocyclic derivatives, their preparation and medicinal products
  申请人：Rhone-Poulenc Sante

  公开号：US05114949A1

  公开（公告）日：1992-05-19

  Compounds are disclosed of formula: R.sub.1 --(CH.sub.2).sub.n --Het in which R.sub.1 represents a residue of formula ##STR1## X represents a hydrogen atom or an alkyl radical, Y represents a hydrogen atom or an alkyl or alkoxy radical, Z represents an alkyl radical, n is equal to 2 or 3, Het represents a substituted piperidino (substituted at the 4-position with a 1-indenylidene, 1-indenyl or 1-indanyl radical or with a chain --(CH.sub.2).sub.m --R.sub.2 or .dbd.CH--R.sub.2), substituted 1,2,3,6-tetrahydro-1-pyridyl (substituted at the 4-position with a chain --(CH.sub.2).sub.m --R.sub.2), m is equal to 1 or 2, and R.sub.2 represents an optionally substituted 2- or 3-indolyl radical, a 1- or 2-indanyl, 1- or 2-indenyl, an optionally substituted 1,2,3,4-tetrahydro-5H-pyrido[4,3-b]indol-2-yl radical, a 1,2,3,4-tetrahydro-3-quinolyl radical, an optionally substituted 1,2,3,4-tetrahydro-2-naphthyl radical or a 1-indolyl radical, their preparation and medicinal products containing them.

  揭示了具有以下结构的化合物：R.sub.1--(CH.sub.2).sub.n--Het，其中R.sub.1代表以下结构的残基##STR1##X代表氢原子或烷基基团，Y代表氢原子或烷基或烷氧基团，Z代表烷基基团，n等于2或3，Het代表取代的哌啶基（在4位取代有1-茚基亚甲基、1-茚基或1-茚基基团或具有链--(CH.sub.2).sub.m--R.sub.2或.dbd.CH--R.sub.2)，取代的1,2,3,6-四氢-1-吡啶基（在4位取代有链--(CH.sub.2).sub.m--R.sub.2），m等于1或2，R.sub.2代表可选取代的2-或3-吲哚基团，1-或2-茚基、1-或2-茚基、可选取代的1,2,3,4-四氢-5H-吡啶并[4,3-b]吲哚-2-基团、1,2,3,4-四氢-3-喹啉基团、可选取代的1,2,3,4-四氢-2-萘基团或1-吲哚基团，它们的制备以及含有它们的药物产品。
• Derivatives of (AZA)naphthalenesultam, their preparation and
  申请人：Rhone-Poulenc Sante

  公开号：US05021420A1

  公开（公告）日：1991-06-04

  This invention relates to a compound ##STR1## in which R.sub.1 represents a 1,2,3,6-tetrahydro-1-pyridyl radical substituted in the 4-position by (a) a phenyl radical, (b) a phenyl radical substituted by a halogen atom or an alkyl, hydroxy or alkoxy radical, (c) a 3-indolyl radical, (d) a 3-indolyl radical substituted on the nitrogen atom by an alkyl or alkylcarbonyl radical and/or in the 5-position by a halogen atom or (e) a 3-(5-hydroxyindolyl) radical. a 1-piperazinyl radical substituted in the 4-position by (a) a phenyl radical, (b) a phenyl radical substituted by an alkoxy, alkyl, hydroxy, nitro or amino radical or a halogen atom, (c) a 1,2-benzisothiazol-3-yl radical, (d) a 1,2-benzisoxazol-3-yl radical or (e) a 2-pyridyl radical. a piperidino radical substituted in the 4-position by (a) a phenyl radical, (b) a phenyl radical substituted by a halogen atom or a hydroxy, alkyl or alkoxy radical, (c) two phenyl radicals, (d) a bis(4-fluorophenyl)methylene radical, (e) a 4-fluorobenzoyl radical, (f) a 2-oxo-1-benzimidazolinyl radical, (g) a 2-oxo-1-benzimidazolinyl radical substituted in the 3-position by an alkylcarbonyl or benzoyl radical, (b) a hydroxy radical and a phenyl radical optionally substituted with an alkyl, alkoxy or hydroxy radical or a halogen atom, (i) a 3-indolyl radical, (j) a 3-indolyl radical substituted on the nitrogen atom by an alkyl or alkylcarbonyl radical and/or in the 5-position by a halogen atom or (k) a 3-(5-hydroxyindolyl) radical. either: R.sub.2 and R.sub.3, which are identical, represent a hydrogen or halogen atom and R.sub.4 represents a hydrogen atom or R.sub.2 and R.sub.4 represent a hydrogen atom and R.sub.3 represents a halogen atom or an acetylamino radical or R.sub.2 and R.sub.3 represent a hydrogen atom and R.sub.4 represents a halogen atom and R.sub.5 represents a --CH.dbd. group. or R.sub.2, R.sub.3 and R.sub.4 represent a hydrogen atom and R.sub.5 represents a nitrogen atom. R.sub.6 represents an alkylene chain containing 2 to 4 carbon atoms or a propylene chain substituted in the 1- or 3-position by an alkyl radical or in the 2-position by an alkyl, alkoxy, hydroxy, dialkylamino, piperidino, morpholino or thiomorpholino radical, with the reservation that when R.sub.6 represents a propylene radical substituted in the 2-position by a dialkylamino, piperidino, morpholino or thiomorpholino radical, R.sub.1 cannot be a radical containing a hydroxy radical, and their salts, are useful in therapy for their ability to block serotonin receptors.

  本发明涉及一种化合物##STR1##在该化合物中，R.sub.1代表在4位被(a)苯基取代的1,2,3,6-四氢-1-吡啶基基团，(b)被卤原子或烷基、羟基或烷氧基取代的苯基，(c)3-吲哚基，(d)氮原子上被烷基或烷基羰基基团取代和/或在5位被卤原子取代的3-吲哚基，或(e)3-(5-羟基吲哚基)基团；在4位被(a)苯基，(b)被烷氧基、烷基、羟基、硝基或氨基取代的苯基，或卤原子取代的苯基，(c)1,2-苯并噻唑-3-基团，(d)1,2-苯并噁唑-3-基团或(e)2-吡啶基取代的1-哌嗪基团；在4位被(a)苯基，(b)被卤原子或羟基、烷基或烷氧基取代的苯基，(c)两个苯基，(d)双(4-氟苯基)甲基基团，(e)4-氟苯甲酰基团，(f)2-氧代-1-苯并咪唑啉基团，(g)在3位被烷基羰基或苯甲酰基团取代的2-氧代-1-苯并咪唑啉基团，(b)羟基和苯基，后者可选地被烷基、烷氧基或羟基或卤原子取代，(i)3-吲哚基，(j)氮原子上被烷基或烷基羰基基团取代和/或在5位被卤原子取代的3-吲哚基，或(k)3-(5-羟基吲哚基)基团；或者：R.sub.2和R.sub.3，它们相同，代表氢或卤原子，R.sub.4代表氢原子，或R.sub.2和R.sub.4代表氢原子，R.sub.3代表卤原子或乙酰氨基基团，或R.sub.2和R.sub.3代表氢原子，R.sub.4代表卤原子，R.sub.5代表-CH.dbd.基团。或R.sub.2，R.sub.3和R.sub.4代表氢原子，R.sub.5代表氮原子。R.sub.6代表含有2到4个碳原子的烷基链或在1位或3位被烷基基团取代的丙烯基链，或在2位被烷基、烷氧基、羟基、二烷基氨基、哌啶基、吗啉基或硫代吗啉基团取代的丙烯基链，但是当R.sub.6代表在2位被二烷基氨基、哌啶基、吗啉基或硫代吗啉基团取代的丙烯基时，R.sub.1不能是含有羟基团的基团，它们的盐，因其阻断5-羟色胺受体的能力，在治疗中具有用途。
• Derivatives of (AZA) naphthalensultam, their preparation and
  申请人：Rhone-Poulenc Sante

  公开号：US05036075A1

  公开（公告）日：1991-07-30

  This invention relates to a compound of the formula: ##STR1## in which R.sub.1 represents a 1,2,3,6-tetrahydro-1-pyridyl radical substituted in the 4-position. a 1-piperazinyl radical substituted in the 4-position. a piperidino radical substituted in the 4-position either: R.sub.2 and R.sub.3, which are identical, represent a hydrogen or halogen atom and R.sub.4 represents a hydrogen atom or R.sub.2 and R.sub.4 represent a hydrogen atom and R.sub.3 represents a halogen atom or an acetylamino radical or R.sub.2 and R.sub.3 represent a hydrogen atom and R.sub.4 represents a halogen atom and R.sub.5 represents a --CH.dbd. group. or R.sub.2, R.sub.3 and R.sub.4 represent a hydrogen atom and R.sub.5 represents a nitrogen atom. R.sub.6 represents an alkylene chain containing 2 to 4 carbon atoms or a propylene chain substituted in the 1- or 3-position by an alkyl radical or in the 2-position by an alkyl, alkoxy, hydroxy, dialkylamino, piperidino, morpholino or thiomorpholino radical, and their salts, are useful in therapy for their ability to block serotonin receptors.

  本发明涉及一种式为：##STR1##其中R.sub.1代表在4位取代的1,2,3,6-四氢-1-吡啶基基团，4位取代的1-哌嗪基基团或4位取代的哌啶基基团，其中：R.sub.2和R.sub.3相同，代表氢或卤素原子，R.sub.4代表氢原子，或R.sub.2和R.sub.4代表氢原子，R.sub.3代表卤素原子或乙酰氨基基团，或R.sub.2和R.sub.3代表氢原子，R.sub.4代表卤素原子，R.sub.5代表--CH.dbd.基团，或R.sub.2、R.sub.3和R.sub.4代表氢原子，R.sub.5代表氮原子。R.sub.6代表含有2至4个碳原子的烷基链或在1-或3-位被烷基基团取代的丙烯基链，或在2-位被烷基、烷氧基、羟基、二烷基氨基基团、哌啶基、吗啉基或硫代吗啉基取代的丙烯基链，以及它们的盐，用于治疗因其阻断5-羟色胺受体的能力而具有的功效。
• Collins, Michael; Lasne, Marie-Claire; Barre, Louisa, Journal of the Chemical Society. Perkin transactions I, 1992, # 23, p. 3185 - 3188
  作者：Collins, Michael、Lasne, Marie-Claire、Barre, Louisa

  DOI：——

  日期：——
• J, Med. Chem. 1991, 34, 2477-2483
  作者：

  DOI：——

  日期：——